Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: originally (45), firstly (24), primarily (85)

MyelomaBortezomib IV DexamethasonePabinostat 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (21 day) Regimen • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-21day-Ver1.1.pdf

IRD(40)-Dexamethasone_40_Ixazomib-Lenalidomide

Description: Chemotherapy Protocol Myeloma IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (40) - Dexamethasone (40)-Ixazomib-Lenalidomide Indication • Ixazomib and le
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD40-Dexamethasone-40-Ixazomib-Lenalidomide.pdf

IRD(20)-Dexamethasone_20_Ixazomib-Lenalidomide

Description: Chemotherapy Protocol Myeloma IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Indication • Ixazomib and le
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD20-Dexamethasone-20-Ixazomib-Lenalidomide.pdf

Nivolumab Ver 1.1 skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable or metastatic) melanoma in a
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf

Nivolumab 480mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its marketing authorisation, as an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf

Nivolumab 240mg skin

Description: Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its marketing authorisation, as an
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metastatic BRA
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Nivolumab_240mg

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • The treatment of recurrent or metastatic squamous
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf

Nivolumab

Description: Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous cell carcinoma of the head and n
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Cystic fibrosis diabetes - patient information

Description: This factsheet explains what to expect when you are tested for cystic fibrosis diabetes (CFD).
Url: /Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Cystic-fibrosis-diabetes-2635-PIL.pdf

161 to 170 of 194

Previous … 15 16 17 18 19 … Next